Abstract
An excessive inflammatory response accompanies the initial stages of severe infection and appears to contribute to organ system failure and death in this setting [1–3]. A number of immunomodulatory therapies aimed at decreasing the dysregulated inflammatory response have been examined in patients with sepsis (Table 1). Despite initially encouraging results with many of these approaches in Phase II clinical trials, larger Phase III studies have not demonstrated benefit. In contrast to the lack of effect of immunomodulatory agents in sepsis, therapies directed against specific pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α or interleukin (IL)-1,have produced remarkable clinical response in diseases such as rheumatoid arthritis and Crohn’s disease [4–6].
Some immunomodulatory therapies examined in sepsis
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abraham E (1997) Therapies for sepsis. Emerging therapies for sepsis and septic shock. West J Med 166:195–200
Parrillo JE, Parker MM, Natanson C, et al (1990) Septic shock in humans. Ann Intern Med 113:227–242
Zeni F, Freeman B, Natanson C (1997) Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 25:1095–1100
Targan SR, Hanauer SB, van Deventer S J, et al (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. New Engl J Med 337:1029–1035
Lorenz HM, Antoni C, Valerius T, et al (1996) In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J Immunol 156:1646–1653
Elliott MJ, Maini RN, Feldmann M, et al (1994) Repeated therapy with monoclonal antibody to tumor necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344:1125–1127
Bone RC, Balk RA, Cerra FB, et al (1992) ACCP/SCCM consensus conference: Definitions for sepsis and organ failure and guidehnes for the use of innovative therapies in sepsis. Chest 101:1644–1655
Bone RC, Fisher Jr. CJ, Clemmer TP, et al (1989) Sepsis syndrome: A valid clinical entity Crit Care Med 17:389–393
Abraham E, Wunderink R, Silverman H, et al (1995) Monoclonal antibody to human tumor necrosis factor alpha (TNF MAb): Efficacy and safety in patients with the sepsis syndrome. JAMA 273:934–941
Cohen J, Carlet J (1996) INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. Crit Care Med 24:1431–1440
Abraham E, Glauser MP, Butler T, et al (1997) p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. JAMA 277:1531–1534
Opal SM, Fisher CJ, Pribble JP, et al (1997) The confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 25:1115–1124
Abraham E, Anzueto A, Gutierrez G, et al (1998) Monoclonal antibody to human tumor necrosis factor alpha (TNF Mab) in the treatment of patients with septic shock: A multi-center, placebo controlled, randomized, double-blind clinical trial. Lancet 351:929–933
Zanetti G, Heumann D, Gerain J, et al (1992) Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. J Immunol 148:1890–1897
Fisher CJ Jr., Agosti JM, Opal SM, et al (1996) Treatment of septic shock with the tumor necrosis factor receptor Fc fusion protein. N Engl J Med 334:1697–1702
Sprung CL, Finch RG, Thijs LG, Glauser MP (1996) International sepsis trial (INTERSEPT): role and impact of a clinical evaluation committee. Crit Care Med 24:1441–1447
Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC (1990) Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348:550–552
Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA (1991) A specific receptor antagonist for interleukin-1 prevents Escherichia coli-induced shock. FASEB J 5:338–343
Hawes AS, Fischer E, Marano MA, et al (1993) Comparison of peripheral blood leukocyte kinetics after live Escherichia coli, endotoxin, or interleukin-1 alpha administration. Studies using a novel interleukin-1 receptor antagonist. Ann Surg 218:79–90
Fischer E, Marano MA, Van Zee KJ, et al (1992) Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 89:1551–1557
Fisher CJ Jr., Slotman GJ, Opal SM, et al (1994) Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. The IL-1RA Sepsis Syndrome Study Group. Crit Care Med 22:12–21
Fisher CJ Jr, Dhainaut JF, Opal SM, et al (1994) Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-bUnd, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271:1836–1843
Tracey KJ, Fong Y, Hesse DG, et al (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330:662–664
Fong Y, Tracey KJ, Moldawer LL, et al (1989) Antibodies to cachectin/TNF reduce interleukin-1 and interleukin-6 appearance during lethal bacteremia. J Exp Med 170:1627–1633
Hinshaw LB, Tekamp-Olson P, Chang AC, et al (1990) Survival of primates in LDioo septic shock following therapy with antibody to tumor necrosis factor (TNF). Cire Shock 30:279–292
Van Zee KJ, Moldawer LL, Oldenburg HAS, et al (1996) Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081. J Immunol 156:2221–2230
Hinshaw LB, Emerson TE Jr., Taylor FB Jr., et al (1992) Lethal S. aureus shock in primates: prevention of death with anti-TNF antibody J Trauma 33:568–573
Vincent JL, Bakker J, Marecaux G, Schandene L, Kahn RJ, Dupont E ( 1992) Administration of anti-TNF antibody improves left ventricular function in septic shock patients. Results of a pilot study Chest 101:810–815
Dhainaut JF, Vincent JL, Richard C, et al (1995) CDP571, a humanized antibody to human tumor necrosis factor-α: Safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. Crit Care Med 23:1461–1469
Reinhart K, Wiegand-Lohnert C, Grimminger F, et al (1996) Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study Crit Care Med 24:733–742
Giroir BP, Quint PA, Barton P, et al (1997) Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis. Lancet 350:1439–1443
Bone RC (1994) Gram-positive organisms and sepsis. Arch Intern Med 154:26–34
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Abraham, E. (2002). Cytokine Neutralization: An Overview. In: Marshall, J.C., Cohen, J. (eds) Immune Response in the Critically Ill. Update in Intensive Care Medicine, vol 31. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-57210-4_25
Download citation
DOI: https://doi.org/10.1007/978-3-642-57210-4_25
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-42589-2
Online ISBN: 978-3-642-57210-4
eBook Packages: Springer Book Archive